BROOKLYN IMMUNOTHERAPEUTICS, INC.

(BTX)
  Report
Delayed Nasdaq  -  04:00 2022-08-12 pm EDT
0.5701 USD   +2.57%
08/11BROOKLYN IMMUNOTHERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
08/11Brooklyn ImmunoTherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
08/05BROOKLYN IMMUNOTHERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2021 2022 2023 2024
Capitalization1 21732,8--
Enterprise Value (EV)1 21732,832,832,8
P/E ratio -1,48x-1,08x-1,08x-0,98x
Yield ----
Capitalization / Revenue ----
EV / Revenue ----
EV / EBITDA ----
Price to Book ----
Nbr of stocks (in thousands) 52 04457 469--
Reference price (USD) 4,170,570,570,57
Announcement Date 04/15/2022---
1 USD in Million
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2021 2022 2023 2024
Net sales1 ----
EBITDA ----
Operating profit (EBIT)1 -114-27,7-28,8-31,6
Operating Margin ----
Pre-Tax Profit (EBT)1 -122-27,7-28,8-31,6
Net income1 -122-27,7-28,8-31,6
Net margin ----
EPS2 -2,82-0,53-0,53-0,58
Dividend per Share ----
Announcement Date 04/15/2022---
1 USD in Million
2 USD
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4
Net sales1 -----
EBITDA -----
Operating profit (EBIT)1 -9,11-6,30-13,9-7,20-7,48
Operating Margin -----
Pre-Tax Profit (EBT)1 -8,46-9,38-3,41-7,20-7,48
Net income1 -8,48-9,38-3,41-7,20-7,48
Net margin -----
EPS2 --0,17-0,06-0,14-0,14
Dividend per Share -----
Announcement Date 04/15/202207/01/202208/11/2022--
1 USD in Million
2 USD
Estimates
Balance Sheet Analysis
Fiscal Period: December 2021 2022 2023 2024
Net Debt ----
Net Cash position ----
Leverage (Debt / EBITDA) ----
Free Cash Flow1 --21,2-22,0-24,3
ROE (Net Profit / Equities) ----
Shareholders' equity1 ----
ROA (Net Profit / Asset) ----
Assets1 ----
Book Value Per Share ----
Cash Flow per Share ----
Capex ----
Capex / Sales ----
Announcement Date 04/15/2022---
1 USD in Million
Estimates
Key data
Capitalization (USD) 32 762 847
Number of employees 10
Free-Float 73,4%
Free-Float capitalization (USD) 24 050 206
Avg. Exchange 20 sessions (USD) 285 735
Average Daily Capital Traded 0,87%
EPS & Dividend